Cargando…
Rapamycin suppresses postnatal muscle hypertrophy induced by myostatin-inhibition accompanied by transcriptional suppression of the Akt/mTOR pathway
Myostatin (MSTN) is a well-known negative growth factor of muscle mass, and studies have shown that MSTN-inhibition would be a potential strategy to treat muscle atrophy seen in various clinical conditions. Recent studies suggest that MSTN-inhibition induces skeletal muscle hypertrophy through up-re...
Autores principales: | Choi, Dong hyuck, Yang, Jinzeng, Kim, Yong Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362869/ https://www.ncbi.nlm.nih.gov/pubmed/30805561 http://dx.doi.org/10.1016/j.bbrep.2018.12.009 |
Ejemplares similares
-
Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin
por: Winbanks, Catherine E., et al.
Publicado: (2012) -
Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer
por: Liu, Tao, et al.
Publicado: (2021) -
Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition
por: MacDonald, Elizabeth M., et al.
Publicado: (2014) -
Lysophosphatidic Acid Is Associated With Cardiac Dysfunction and Hypertrophy by Suppressing Autophagy via the LPA3/AKT/mTOR Pathway
por: Yang, Jinjing, et al.
Publicado: (2018) -
Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity
por: HAN, XIAO, et al.
Publicado: (2014)